Abstract:Background Breath analysis science was featured in three organized sessions at this year's Pittsburgh Conference and Exposition, or 'PittCon 2012' (http://www.pittcon.org/). As described in previous meeting reports, PittCon is one of the largest international conferences for analytical chemistry and instrumentation, typically attracting about 20 000 attendees and 1000 commercial exhibitors (Pleil 2010, 2011). This year the conference was held in Orlando, Florida, USA at the Orange County Conference Center. In the past few years, breath analysis science has taken on an ever-increasing role at PittCon through the success of the International Association of Breath Research (IABR) and the Journal of Breath Research (JBR). We have also had a presence at a recent conference of the Submarine Air Monitoring and Air Purification (SAMAP) organization in Taranto, Italy, wherein breath analysis and other biomarker measurements are taking on an increasingly important role in assessing exposures and health in artificial atmospheres including submarines, aircraft and spacecraft (Pleil and Hansel 2012). In 2012, members of IABR organized or participated in three distinct PittCon events: a contributed technical session, a conferee networking session, and an invited symposium series. The common thread among these three different conferencing settings was the concept of 'non-invasive' environmental, medical, and diagnostic biomarker assessment. Of particular interest was how breath is being considered more and more mainstream as a biological medium, and is often discussed favorably as complementary or alternative to blood and urine measurements. Technical session: non-invasive biomedical analysis This was our JBR/IABR signature session organized and co-chaired by Dr Joachim Pleil from the US Environmental Protection Agency and Dr Wolfram Miekisch1 from the Rostock University Hospital in Rostock, Germany. Our speakers were carefully selected to cover a broad range on breath diagnostic techniques with some topics including urinary biomarkers, the 'other' non-invasive (or at least minimally invasive) biomarker approach. The first presentation, 'Non-invasive biomedical analysis—dawning of a new area of diagnostic information' was given by Professor Jochen K Schubert2 from the University of Rostock, Germany. Professor Schubert discussed the important role that diagnostic tests play in life-saving therapy and in early stage disease detection. He particularly stressed the increasing need for non-invasive techniques (especially for critical care medicine) and for rapid assessments preferably performed at the bedside. He discussed new technologies for instrument miniaturization for breath analysis and presented results showing the potential of real-time mass spectrometers based on proton transfer reactions (PTR). He also gave an intriguing example for a minimally invasive blood test based on a gas-phase (breath) technology wherein specially coated fibers are inserted directly into the blood stream to absorb certain compounds of interest for subsequent desorption analysis using standard solid phase micro-extraction (SPME) methods. Dr Jens Herbig3 from Ionimed Analytik in Innsbruck, Austria gave the second presentation, entitled 'Applications of PTR-MS in medicine and biotechnology'. Dr Herbig began his talk with an introduction to proton-transfer-reaction mass spectrometers (PTR-MS), highlighting benefits of these analytical tools for real-time analysis of volatile organic compounds (VOCs) in biological media, and articulating differences between available quadrupole and time-of-flight (ToF) based detections systems. He then demonstrated how, via real-time monitoring of exhaled breath, PTR-MS instruments can be used to evaluate chemical uptake, distribution and metabolism in the human body. Finally, he showed applications of the PTR-MS systems for real-time monitoring of in vitro systems. An example was given of the analysis of fermentation off-gas produced by micro-organisms. Together these descriptions and examples showed unique advantages of real-time monitoring equipment over classical offline tools, drawing considerable interest from session attendees. Dr Jon Sobus from the US Environmental Protection Agency presented 'Statistical considerations for interpreting urinary biomarker concentrations'. He discussed how urine, like breath, is a preferred sample medium for biomedical analysis since it is available in abundant supply and collected using non-invasive techniques. He highlighted that urinary biomarker measurements are generally reported in units of concentration, and are therefore subject to variations from changing urine output, as well as changing exposure or health state. Dr Sobus stressed that, given this dependence, careful evaluation of urinary biomarker measurements is critical for decision making in medical and public health investigations. He further proposed a mathematical approach to correct for changing urine output; correction factors, based in part on urinary creatinine measurements, used empirical observations of healthy adults made during a recent EPA study. In closing, Dr Sobus highlighted implications of using and not using correction factors for biomedical urine analysis. Dr Sobus was followed by Professor Cristina E Davis4 from the University of California, Davis with a presentation entitled 'Mammalian cell culture headspace volatile organic compounds hold vital clues as putative biomarkers of cellular changes'. Professor Davis described the analysis of VOCs from cell culture using gas chromatography-mass spectrometry (GC-MS) to develop an odor fingerprint. She illustrated how VOC headspace analysis can distinguish between human B cells differing by a single human leukocyte antigen (HLA) gene, demonstrating how VOC analysis can illustrate changes occurring on a cellular level. Professor Davis then showed that different viral infections result in unique fluctuations to VOC fingerprints indicating tremendous biomedical potential. She suggested the potential for such a VOC analysis as a non-invasive technique for diagnosing infections given the development of appropriate sensor devices. Next, Dr Tzipporah M Kormos from the US Environmental Protection Agency presented 'Metabolomics evaluation: perturbations of organic metabolites in human breath and urine'. Dr Kormos provided an overview of the attempts underway in method development at the US EPA for applying non-targeted top-down approaches to link environmental exposures to human health effects. She described the goal of characterizing the human exposome in order to effectively link exposure to health effects. However, she also denoted how the eclectic chemical composition of the exposome poses an analytical challenge requiring a range of instrumentation to effectively characterize its components (including liquid chromatography-mass spectrometry (LC-MS), nuclear magnetic resonance spectroscopy (NMR), immunochemistry, and GC-MS). Dr Kormos stressed the need for non-invasive sampling in such exposure studies as the only way to obtain a sufficient number of biological samples from the general populace in field studies. The sixth presentation of the session, entitled 'Real-time measurements and mathematical modeling of breath biomarkers to address the impact of physiological effects', was presented by Dr Julian King5 of the Austrian Academy of Sciences, Dornbirn, Austria. Here, Dr King presented real-time measurements of VOCs in breath samples, collected during periods of rest, exercise and sleep, and determined using PTR-MS and solid phase micro-extraction (SPME)/GC-MS. Dr King focused on acetone and isoprene as target molecules, and showed how measurements of these analytes, combined with mathematical models, can be used to explore mechanistic relationships governing the general behaviors of VOCs in breath. Dr King suggested that these results provide a basis for experimental design and general guidance for interpreting empirical results. Specifically, he recommended breath gas analysis for evaluating metabolic processes of VOCs, namely storage, transport, and biotransformation, in vivo. Matthew Stiegel from the University of North Carolina at Chapel Hill, NC, gave the seventh talk, entitled 'Correlations of inflammatory cytokines in blood, exhaled breath condensate, and urine'. This talk focused on multi-media biological measurements of interleukins, interferon-γ, and tumor necrosis factor-a made as part of a controlled chamber experiment using human volunteers. Here, the TH1/TH2 cytokines were evaluated as makers of inflammatory/endogenous response to various controlled exposures, including diesel exhaust, ozone, and diesel exhaust plus ozone. Stiegel showed that cytokine levels and patterns changed across media and subjects, and suggested that these changes reflect subject-specific responses to the controlled exposures. He concluded that cytokine levels in blood, exhaled breath condensate (EBC), and urine are probative indicators of exposure and/or endogenous response, and thus, are useful for exposure and health monitoring. Phillip Trefz6 from the University of Rostock, Germany gave the final talk 'Micro extraction techniques as a link between clinical application and hyphenated analytical techniques'. Mr Trefz explained how a current hindrance to the biomedical application of breath analysis is sampling. As analytical instrumentation is not yet a bedside technique, reliable tools are required for breath collection, concentration, and storage in order to enable the detection of trace VOCs. He explained the benefits of needle trap devices (NTDs) over solid phase extraction (SPE) and SPME techniques in terms of sensitivity and sampling time. A comparison of different sorbents showed the possibility of storing samples over a week while retaining high levels of recovery and reproducibility. He then described an interesting pilot study using NTDs to sample from ventilators of patients with various health conditions. Networking session: non-invasive biomedical analysis—the fast, the furious, and the brave—innovative analytical instrumentation for breath gas testing As in past PittCon meetings, the networking session was organized and facilitated by IABR's own Dr Wolfram 'Wolfie' Miekisch. The theme this year was the spectrum of novel instrumentation spanning the range from biomarker discovery, high-throughput analysis, and eventual outpatient or homecare devices. The play on words in the title (taken from recent movies) referred to the three featured underlying analytical regimes for breath-discovery using two dimensional gas chromatography and time of flight mass spectrometry (2D-GC-ToFMS), on-line assessment and screening using PTR-MS, and the use of specific chemical sensors for outpatient monitoring and continuing therapy assessment. After an opening statement and introduction by Dr Miekisch, Dr Jens Herbig began the networking session with a brief introduction of what it takes to have an 'ideal' breath analysis instrument. He stated that the PTR-MS has all four main components of this ideal instrument: sensitivity, specificity, real-time practicality, and accuracy. The fact that it has all four of these necessary elements makes it the instrument to use when doing real-time biomarker discovery or monitoring. The discussion moved from an instrumentation perspective to a more philosophical one as audience members wondered why it was important to have the ability, or even the desire, to use a discovery tool such as the PTR-MS. Opinions given ranged from the need for top-down discovery approaches that involve pattern analysis and perturbations of normal biomarker ranges, to the use of targeted single-compound, or 'low-hanging fruit', analysis that could be perceived as more effective. It was further suggested that PTR-MS is more of an operational instrument, in that it trades off speed of analysis for highly resolved specificity. Other discussions revolved around the issue of 'competition' with blood and urine analysis; the strength of breath analysis in real-time is that it provides access to reactive/intermediary metabolites that otherwise can only be inferred from stable compounds measurements. Joe Binkley7 from Leco Corporation in St. Joseph, MI, followed this enlightening discussion with an introduction to the details of 2D-GC-ToFMS. The instrumentation was presented as a great discovery tool that allowed for a comprehensive analysis of difficult matrices such as that of human breath. The increased chromatographic resolution of GC×GC made possible by orthogonal modes of separation (i.e. boiling point and polarity) as well as increased sensitivity due to the cryo-focusing effects of thermal modulation have lead to increasing use of this technology amongst breath researchers. The practical applications of the instrumentation were immediately compared to those of the PTR-MS. The 2D-GC-ToFMS was shown to be excellent not only in discovery but also with quantification; however, it lacked the ability to do real-time analysis, potentially losing any reactive compounds during the downtime from sampling to analysis. The PTR-MS shines in the real-time arena; however, it lacks the quantification ability of the 2D-GC-ToFMS. The consensus was that neither style of instrumentation was intrinsically 'better' than the other but that they both served the research needs well within their niche applications. Comments were made that 2D GC creates so much data that it takes quite some time to interpret it, but that it is probably the best way to get an appreciation for the breath exposome. The last segment of the session was introduced briefly by Dr Andreas Hengstenberg8 from Draeger, Lübeck, Germany. Draeger is well known for a variety of laboratory and industrial safety products including handheld or portable instrumentation for making air measurements. Dr Hengstenberg commented that blood analysis is still considered to be the gold standard in medical practice and that this is a difficult hurdle to overcome. He presented some thoughts as to how chemical-specific biosensors could be implemented for breath biomonitoring applications with handheld devices that could be used for outpatient or homecare monitoring where blood analysis cannot effectively compete. Dr Hengstenberg led the discussion to the concept of the 'triangle' of breath analysis comprised of the large laboratory discovery instruments (e.g. GC-MS or ToF, LC-MS-MS or ToF, 2D-GC-ToFMS), the real-time multi-components instruments (e.g. PTR-MS or ToF, SIFT-MS), and finally the small, targeted instruments (e.g. chemical sensors, sensor arrays, optical absorption, photoacoustic). The subsequent discussions revolved around the need for all three types of methodologies to be used in parallel. Although the eventual goal is the penetration of non-invasive breath measurement into the home at the personal level, this cannot occur without the continuous discovery and validation from the other two research arenas implementing broad-based analysis. The ensuing audience discussion concluded that specific biosensors could be used to support all three arenas but that the targeted sensors were limited by their compound-specific characteristics Symposium: breath analysis as a non-invasive alternative for medical diagnostics The symposium session for breath analysis was organized by Professor Janusz Pawliszyn9 from University of Waterloo, Canada. Professor Pawliszyn is the inventor of SPME techniques for measuring trace-level organic compounds in complex gas-phase, in the headspace of liquid and solid phase matrices, and even immersed in complex liquid phases such as blood and urine. SPME is now a mainstream technique for all forms of environmental and biomarker research including blood, breath and urine metabolites. Professor Pawliszyn gave a brief introduction about breath analysis and then proceeded to serve as the moderator for the symposium presentations. The first speaker was Professor Raed A Dweik10 from the Cleveland Clinic in Ohio. He presented an overview entitled 'The state of breath analysis: achievements and challenges' wherein he discussed some of the most pressing issues in furthering the acceptance of breath analysis for clinical practice and diagnosis. He used the development of the standardization for nitric oxide (NO) analysis as an example that the rest of breath applications methodology should follow. In particular, he described the painstaking process undertaken by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) as a joint effort to develop specific guidance for NO analysis. Without such efforts and assurances of unambiguous quality, he suggests that breath analysis will not be readily accepted in the clinical and diagnostic communities. In fact, he suggests that physicians want a simple answer for a diagnosis from breath analysis methods like a traffic light where green means healthy, yellow means maybe, and red means disease; he then added, ' . . . but without the yellow'. He was followed by Professor Anton Amann11 from the Austrian Academy of Sciences, Innsbruck Austria who continued with the overview theme with his presentation 'The state of breath analysis: achievements and challenges—analytical perspective'. He discussed recent work in his laboratory that implemented new proton transfer reaction-time of flight mass spectrometry (PTR-ToF-MS) instrumentation to monitor endogenous breath markers in real time. As an example, he demonstrated how the metabolic pathway for isoprene in breath could be traced back to muscle tissue acting as both source and reservoir. His experiments also included analysis of breath during sleep cycles wherein he showed that exhaled isoprene is directly affected by sleep stage, increasing during deep sleep, and decreasing during REM stages. Professor Terence H Risby12 from Johns Hopkins University, Baltimore, gave the next presentation 'Methodological aspects of VOCs collection in real-time breath analysis'. Initially, Professor Risby explained that exhaled organic biomarkers are not unique for different diseases but all reflect specific human biochemical pathways; the probative differences between sick and healthy patients are seen in changes in patterns that depend on how the pathways are affected by the disease. He also stressed the importance of regulating and monitoring the breathing technique of patients during breath collection because humans tend to hyperventilate when they focus on their own breathing. Feedback for depth of inhalation, breath pacing, and exhalation volume is necessary to assure that samples are comparable within and between subjects and among different laboratories. This is accomplished by monitoring exhaled carbon dioxide and differential pressure. He also stressed that external analytical standards made up to simulate the breath matrix are necessary to assure that cross-laboratory results are comparable. Only if diagnostic results can be shown as consistent and accurate will diagnostic breath methods ever be broadly accepted. Dr Joachim D Pleil presented the environmental aspects of discovery research in biomonitoring; his presentation was entitled 'Breath biomarkers in environmental health science: decoding the human exposome'. He discussed new discovery research for distinguishing between the human pulmonary microbiome and endogenous breath biomarkers derived from human metabolism. His examples showed GC-MS results for headspace analyses of cultured anaerobic bacteria known to infect humans, and contrasted them to aerosols collected directly from humans and grown under anaerobic conditions. He also followed up on Professor Risby's concepts regarding breath sampling by introducing new instrumentation from Loccioni Group, San Rosario, Italy, that was adapted to collect EBC using feedback 'coaching' of the subjects. He showed preliminary data that variability in collected volume was reduced by a factor of 10. The final symposium speaker was Dr Heather L Lord13 from University of Waterloo, Canada who presented her research implementing various novel sampling techniques for breath analysis. Her talk was entitled 'Micro-sampling/sample preparation devices for breath analysis' which focused on micro-scale sampling of breath wherein the organic compounds are partitioned away from the bulk breath matrix either through transmission or absorption for subsequent analysis. She explained that the novel membrane and sorbent-based technologies provide a fast and efficient concentration step due to the high surface to volume ratio in contrast to other absorptive devices. This technology is expected to be well suited for miniaturization and application to handheld devices as the sampling technology is essentially passive and requires little, if any, power. Concluding remarks This year's foray of IABR members into the world of PittCon and analytical instrumentation was a successful venture. We had the opportunity to interface with the broader instrument and laboratory equipment manufacturing community. Breath work was well received and we hope to continue to disseminate the message that non-invasive biomarker methodology, especially using breath as a biological medium, is a valuable tool. We intend to continue our relationship with PittCon and encourage the JBR readership to consider attending and contributing to future meetings. We also encouraged our PittCon colleagues to participate in breath-specific endeavors by looking at JBR, the IABR website, and possibly attending the next IABR meeting. The United States Environmental Protection Agency through its Office of Research and Development has subjected this article to Agency administrative review and approved it for publication. References Pleil J D 2010 Meeting Report: breath biomarkers networking sessions at PittCon 2010, Orlando Florida J. Breath Res. 4 029001 Pleil J D 2011 Meeting Report: breath biomarkers networking session at PittCon 2011, Atlanta, GA J. Breath Res. 5 029001 Pleil J D and Hansel A 2012 Submarines, spacecraft and exhaled breath J. Breath Res. 6 019001 1 wolfram.miekisch@uni-rostock.de 2 jochen.schubert@uni-rostock.de 3 jens.herbig@ionimed.com 4 cedavis@ucdavis.edu 5 julian.king@assoc.oeaw.ac.at 6 phillip.trefz@uni-rostock.de 7 joe_binkley@leco.com 8 andreas.hengstenberg@draeger.com 9 janusz@uwaterloo.ca 10 dweikr@ccf.org 11 anton.amann@i-med.ac.at 12 thrisby@jhmi.edu 13 hlord@uwaterloo.ca

Abstract:Foreword The 2011 Conference 'Breath Analysis Summit' was hosted by Antonio Mutti and Massimo Corradi, professors from the University of Parma, Italy. It was held at the Centro Congressi di Parma (Conference Center) in Parma. This was our highest attended breath conference to date, and by all measures, extremely successful. For this editorial the authors solicited comments from the attendees and asked them to provide a paragraph describing a concept or observation from the conference that particularly intrigued them or that instilled an innovative idea for application to their own research. Below is a collection of comments, observations, and 'aha' moments paraphrased from this random and totally unscientific poll of the eclectic group of researchers that work in our field of research. Comments from the attendees One of the many interesting concepts brought out at the conference was in regards to predicting the efficacy of drugs using exhaled breath. Often, inter-individual differences will create a scenario wherein a particular drug works wonderfully in many people, and miserably in others. Anil Modak described a number of isotopically labeled 'probe' molecules that either mimic the action of a specific drug, or at least follow the same metabolic pathway; these can be administered to patients prior to the selection of a therapeutic regimen to see if the intervention would be effective. These probe molecules are designed so that certain metabolites containing an isotopically labeled fragment are eliminated in the breath (generally 13C labeled carbon dioxide). Measuring the levels of such labeled compounds can then demonstrate if the phenotype of the patient is able to metabolize the drug in the expected manner. This simple breath analysis scheme brings us one step closer to personalized medicine and furthermore avoids the complex interpretation of specific gene polymorphisms. Terence H Risby, Johns Hopkins University, Baltimore MD, USA. The selected oral presentations represented one of the highlights of the symposium. Despite the limited time frame (8 minutes only) and the late occurrence (after already more than 6 hours of plenary lectures) the short lectures provided an excellent overview of innovative ideas and the most recent cutting edge research activities in the field. These activities included interesting settings, such as drug or bacterial detection from breath, applications of innovative technology, such as specific sensor systems, as well as basic questions such as the influence of nutrition on breath tests. In my opinion much more space within the breath gas summit should be given to this kind of talk, e.g. in the form of a 'young researcher forum'. {Wolfram Miekisch, University Hospital, Rostock, Germany. I remember well my first breath conference in Prague five years ago. We were all enthusiastic about the potential of non-invasive breath analysis; dogs could sniff cancer, some markers for diseases had already been proposed, sampling techniques were discussed, and analytical techniques struggled for recognition. Looking at this conference five years later one could get the illusion that not many things have progressed—it is easy to make this mistake. We have heard that new technologies tend to follow the hype curve. Initially, this leads to inflated expectations: enthusiastic researchers claim the cure for cancer after finding a simple correlation. Whoever joined the community during this time first planned a clinical study to find markers for cancer within a few weeks—and after that live on the royalties. A valley of disillusionment followed the hype, and enthusiasm was dampened; the only way up is to learn that we cannot jump the line, that the way from exhaling into a device to a clinical test has many small steps inbetween. My overall impression on this excellent conference was that a critical view was present in many talks and more than welcome. Many deficiencies were openly addressed and research with a good quality assurance was valued above fancy results. I like to believe that it seems we are now passing the level from five years ago because we have survived the hype, walked the valley, and are now charging forward with a solid and sustainable approach. Jens Herbig, Ionimed Analytik, Innsbruck, Austria. The conference included many fine posters—too many to discuss them all here. Among the EBC posters (none were actually about particle collection devices such as described by Olin), pH and 8-isoprostane seemed to remain the most frequently useful biomarkers, probably because they do not rely on high particle collection efficiency. Affinity purification of samples as described by Kacer et al for LC-ESI-MS/MS analysis seems like a great idea. More work in this area is needed. Two posters from Uppsala emphasized in more detail points made in brief presentations—there is still much to be understood about eNO dynamics. It seems that we have a way to go before we can reliably partition the sources of eNO. A host of posters on VOCs in exhaled breath suggests that this is currently the most rapidly advancing part of the field. Systems based on various MS technologies, others based on eNose systems, microfluidics or novel micro/nano-sensors, and application of data reduction techniques, such as being developed for microarray data are all making important contributions. Some of these systems probably cost more than a new (inflation adjusted) Bugatti in 1909; it will be interesting to see how long it takes to get a Chevy or Toyota out to market. Donald Milton, University of Maryland, College Park, MD, USA. There was no mention of bad breath at all in any of the overview abstracts on breath testing, and I found that disturbing. So disturbing that I gave it some thought. One of the thoughts was that the breath research community is primarily interested in testing for volatiles linked to diseases. Although bad breath comes primarily from microorganisms on the tongue, the periodontium is the major secondary contributor to oral malodor. Periodontal diseases are, after dental caries, the second most prevalent disease of mankind, are linked to heart disease and are extremely costly and painful. In the light of this, I made last minute changes in my presentation to focus on the possibility of looking for periodontal disease-linked volatiles in the oral cavity. The talk went over well in that I was not pelted with parmesan, no one left in the middle of my presentation, and there was even a question or two from the audience that I did not plant beforehand. Mel Rosenberg, Tel-Aviv University, Israel. When Jens Herbig interrupted Wolfram Miekisch's lecture with late breaking news regarding a new multi-sensor configuration for breath analysis using cubic resonator arrays, it created a flurry of writing activity in the audience around me. I had to smile because I knew what was coming; Jens introduced his array as a handful of common dice that he shook and threw on the floor. His point was that we often over interpret complex data until we find any, possibly random, correlations that might explain our results. He demonstrated that even with completely randomized data from his cubic array, he could find apparently robust data associations that we have started referring to as 'voodoo' correlations. Although tongue-in-cheek, this demonstration was only the tip of the proverbial iceberg for discussions. Later on, Michael Phillips presented a talk regarding pattern recognition and his approaches for challenging case-control discrimination equations with randomized data. A number of other speakers addressed this same issue by considering the 'ROC' curves for the various outcomes of their research. In my mind, this aspect of the conference was groundbreaking. We, as a group at IABR, are becoming much more sophisticated in our data interpretations. Joachim Pleil, US EPA, Research Triangle Park, NC, USA. My overall view of breath measurement has been that '...breath tests are like automobiles one hundred years ago: good enough to be useful in a limited way, but with a huge variety of competing designs all struggling to find their own markets...'. However, now we are starting to close in on standardization of the collection methods and of the data interpretation methods; this was made abundantly clear in the many talks and also by the vendors' exhibits at the Parma IABR meeting. The technologies ran the gamut from direct concentration methods using needle trap devices to feedback-regulated breath technique collections for sorbent samples and EBC, and direct measurement mass spectrometry systems. The underlying theme of the conference that we need to focus on precision and quality assurance is a heartening development, and is of crucial importance to the acceptance of breath measurements as an important constituent of diagnostic and critical care medicine in the future. Michael Phillips, Menssana Research, Newark, NJ, USA. One of the most intriguing developments in the field is real-time analysis of exhaled breath, even in breath-to-breath resolution. Julian King presented particularly impressive data on isoprene. He showed that the concentration of isoprene increases by a factor 4–5 during exercise on a stationary bicycle. Isoprene even increases by a factor of 2 when only a leg is contracted. In addition, left or right leg and left or right arm can separately be depleted from isoprene by exercise. During sleep, isoprene concentration shows characteristic peaks during changes in sleep stage or during arousals and movements of legs, arms or head. Modeling of these concentration time series is possible using the respective measurement results of cardiac output and alveolar ventilation. This allows us to estimate the isoprene production and metabolization rates in the human body. Anton Amann, Austrian Academy of Sciences and Innsbruck Medical University, Innsbruck, Austria. The conference in Parma was a great opportunity for all the 'breath friends' to meet the researchers and the people that have made, and are now making, breath analysis an interesting field of research and a promising area for the future. As technology developers, we are not directly involved in the research of the field, but my impression is that every day zwe are coming closer to understand what is really needed. A multi-disciplinary approach and a comparison with other established and successful medical device markets might be very helpful to help companies and researchers to work together and to understand the benefits and the market potentiality of breath diagnostics. Claudio Loccioni, Loccioni Humancare, Angeli di Rosora, Ancona, Italy. As a researcher who studies exhaled breath condensate (EBC), I was intrigued by the work of Anna-Carin Olin who studies size-fractionation of breath-borne aerosols. She specifically demonstrated that breathing technique radically alters the EBC content of aerosol particles over orders of magnitude. She also assayed the particles for specific protein content based on exhalation pattern. What was surprising to me was how much human albumin could be recovered in EBC (33 ng 100L -1 breath under certain conditions). In my work, this is very important in that we have been relegated to using human plasma to assess albumin protein adducts; this inspiration could lead to a much less invasive way to assay human protein adducts by using breath instead of blood samples. Anonymous. Although it could have been known from daily clinical routine, the lack of proven benefit of exhaled NO measurement in the treatment of asthma and other inflammatory airway diseases was among the most striking news from the breath analysis summit 2011. As Peter Barnes pointed out in his lecture, a significant benefit of exhaled NO analysis in the treatment of asthma could only be demonstrated in subgroups such as obese asthmatics. Similarly, Ildiko Horvath could not provide positive news concerning exhaled breath condensate (EBC). Despite more than ten years of intense scientific effort in this field basic, problems such as reproducibility of sampling or standardization of results have not been solved yet. EBC, therefore, does not yet hold promise for clinical application. On a more positive note, intriguing and scientifically important news on data processing in breath analysis was presented by Wolfram Miekisch and Jens Herbig. The vivid discussion on this topic underlined the paramount importance of these issues. The assumption may be made that many of the results presented in breath research have been affected by problems of data processing. In the future meticulous attention will have to be paid to confounding variables, 'voodoo correlations' and the ratio between number of parameters and number of independent measurements. Jochen Schubert, University Hospital Rostock, Germany. In general all presentations were of a very high standard. Two addressed aspects of particular interest to me. On the instrumentation side, I thought the application of the SIONEX portable GC/DMS/IMS configuration for analysis of exhaled breath by Gunter Becher was a practical and relatively inexpensive technique. The instrumentation offers considerable potential for on-site use due to its small size and the use of air as a carrier gas. With respect cancer diagnosis, correlation between certain common VOCs in exhaled breath and cancers was discussed in many presentations. It was assumed that the metabolites from cancer cells are different than those from normal cell lines. Environmental contaminants vary in concentration and nature depending on location and the materials used in that environment. In addition, it was pointed out that exhaled breath VOCs are affected by diet and this has led to erroneous conclusions in correlations of VOCs with cancers. Hence, the robustness of the correlation between cancer and VOCs may be fragile particularly when considering small molecules at the end of the metabolic pathways. VOCs from head-space analysis of cell cultures are also problematic in terms of being culture specific so there is a difficulty in establishing robust correlations between VOCs and cell lines in vitro and in vivo experiments. The road to cancer diagnosis by exhaled breath analysis is a difficult one. Wally Mazurek, Defence Science and Technology Organization, Melbourne, Australia. I was intrigued by the progress made in the instrumentation for collecting breath samples in a consistent manner. For gas phase samples, Dietmar Hein demonstrated a combination sampler and analytical injection tool based on syringes coated internally with sorbent material named 'needle trap device' that can concentrate a breath sample and subsequently be used also as part of a GC-MS auto-sampler injection. Claudio Loccioni and Adolpho Russo demonstrated new sampling technology wherein the subject is coached electronically via biofeedback as to breathing frequency and tidal volume; the instrument is designed to either capture gas phase breath samples onto adsorbent tubes, or to capture exhaled breath condensate using commercially available 'R-tube' devices. As one who is greatly concerned about repeatability statistics and variance components in breath data, this focus, with pragmatic solutions, comes as a great relief. Anonymous. Isoprene is one of the most abundant and most studied organic compounds in exhaled breath and yet I learned something intriguing about this molecule again. Anton Amann presented his research using real-time breath analysis where he measured isoprene in an exercising subject. The results were as expected; exercise initially increases breath isoprene concentration. He then had the subjects exercise using only one leg or one arm to decrease isoprene, and then switch to exercising the other leg and caused the isoprene to go up again, albeit temporarily. Isoprene seems to be localized and stored in muscle reservoirs; who knew? Very elegant experiment! Anonymous. Raed Dweik gave a very insightful presentation on the two-decade-long history of the developments of exhaled NO in asthma patients. He covered the initial discovery of the presence of higher levels of NO in exhaled breath of untreated asthma patients and detailed the progress made in making the instrumentation more accessible to the point of care setting. The standardization of NO measurement in exhaled breath has established approved ATS guidelines in 2005 that make FENO measurements simple and easy to perform for diagnosis and monitoring of efficacy of treatment. He emphasized the need of researchers developing new diagnostic tests, software or hardware developers of instrumentation for measuring breath VOC's, and physicians the end users of the tests to work together cohesively to ensure a brighter future for breath testing in the medical field. Anil Modak, Cambridge Isotope Laboratories, Boston, MA, USA. The use of electronic noses and similar chemical sensor arrays for assessing VOCs patterns in breath was discussed by Mona Syhre. These instruments have the capability to quickly compare patterns between samples to potentially differentiate between healthy and affected patients. The inability to assign individual compounds to specific responses is not considered an important drawback when using a well-established pattern 'library'. What struck me from this presentation was the cautionary tale about the availability and use of such library patterns. Apparently, there are numerous manufacturers of e-noses that all use different sensor technologies; as such, each type of instrument must be trained separately and different types cannot use a common library. Furthermore, when a manufacturer changes sensors or discontinues a particular instrument, the developed library data could become useless. Perhaps there is a way to apply some of the heat-mapping and variable clustering techniques described by Joachim Pleil to consolidate the patterns into a general rule set before the specific instruments are no longer available. Anonymous. Valuable information was presented on both instrumental development and numerous applications. The 30 minute talks offered a very good overview of the breath analysis so far, and the short talks were clear, well structured and relevant; I found this to be an overall interesting symposium. My observation is that the level of the meeting could be further improved if there were more time for interaction between the participants, especially of the younger scientists with the established order (e.g. in a series of specific conference events). I would have liked to see more time allocated to the shorter oral talks and longer, more formal poster sessions. Simona Cristescu, Radboud University, Nijmegen, The Netherlands. As a first remark, I was very impressed how Jens Herbig pointed out the intrinsic pitfalls of data processing in breath gas analysis. In my opinion, one lesson to be learnt from his presentation is that we generally need to become much more critical with respect to the adequacy of the statistical techniques employed for summarizing our research. Far too often, voodoo correlations are overseen or neglected, methods are applied without checking the underlying requirements (e.g., linear discriminant analysis on potentially non-normally distributed, heteroscedastic data), samples are postulated as independent where they aren't and correlations are mistaken as causalities. The increasing awareness with respect to these issues will certainly contribute towards drawing more robust and reliable conclusions from our measurements. Secondly, I was happy to see that the focus of breath gas analysis is now including an increasing number of applications in general biomonitoring. Tracking the status of critically ill or anesthesized patients (Jochen Schubert), estimating enzyme activity (Anil Modak), investigating respiratory physiology (Michael Hlastala) or quantifying environmental exposure (Joachim Pleil) are all great examples underlining the potential of breath gas analysis beyond purely diagnostic purposes. Julian King, Austrian Academy of Sciences, Dornbirn, Austria. As is necessarily the case with every (scientific) meeting, some contributors must pull the short straw and have their presentation allotted to the final session of the conference. These speakers often have their work cut out trying to captivate an audience that is eager to wrap things up and return to their awaiting families back home. One of the 'unlucky' candidates at the Breath Analysis Summit 2011 was Julian King, whose talk was scheduled as the penultimate of the conference. Julian rose to the challenge and offered an engrossing presentation that focused on real-time measurements of breath (using PTR-MS) and their utility for characterizing the underlying physiology relating to production and exhalation of endogenous VOCs. After reminding us of the potential danger of losing information in the 'snapshot' of off-line analysis, he proceeded with presenting some fascinating insights into the impact of physiological conditions (exercise/resting, hyper/hypoventilation, change of posture) on the variability of breath VOC concentrations. He then went on to elaborate on the idea of peripheral tissue sources of isoprene that had been addressed by Anton Amann earlier in the week and presented physiologically-based models to predict breath concentrations of compounds such as isoprene and acetone, as well as the anesthetic sevoflurane. In my opinion one of the most pressing issues in the field of breath research at present is to understand the principal production and excretion of endogenous compounds and to establish their 'normal' concentration levels. Given the cautionary note made by Terence Risby in his presentation that all potential disease biomarkers must be of endogenous—and not exogenous—origin, it is imperative to have thorough knowledge of a healthy breath gas profile to avoid misinterpretation of data. Research such as was presented in this talk is bringing us closer to achieving this goal. Jonathan Beauchamp, Fraunhofer IVV, Freising, Germany. As a major sponsor of the Conference, we at Oxford Medical Diagnostics are delighted to see that the community still regards breath analysis as a major area for medical research, and we are pleased to see the progress that is being made. Many speakers have indicated the necessary complexity of breath research. As manufacturers of sensitive instruments for gas analysis, we would like to make a comparison between the state of breath research today and an area of science which was considered to be as complex (and to some as intractable) some forty years ago. The area is that of atmospheric chemistry. A skeptic then would not have believed how atmospheric measurements of trace gas phase species at the sorts of levels mentioned in this meeting would be possible (and even routine) and how chemical models have evolved to explain and to predict future atmospheric trends. We have heard a great deal about the importance of NO in breath analysis. The equivalent small molecule in atmospheric chemistry is the OH radical, and this is present in the atmosphere at considerably less than 1 pptv. It is now routinely measured at these levels in field and aircraft campaigns. The development of the technology to do this has come about through a need to know its concentration: we can be assured that if suitable breath markers become identified, then similar efforts to develop suitable instrumentation to measure them will take place. We have heard a great deal about sampling problems—again; these issues have been faced by other communities and it is gratifying to see that good progress is being made in breath sampling. We are delighted to have been associated with this excellent meeting, and look forward to welcoming you to Oxford in September 2012 for the next one. Rowland Smith, Oxford Medical Diagnostics, Oxford, UK. The last word As we see from the comments above, the meeting was definitely not boring! This year, there were some new themes and some new challenges. The issues dealing with measurement (sampling and analysis) quality, biochemical understanding, and data interpretation were probably the most discussed. But, unlike past conferences, we all seem to be converging on a consensus that the exploratory research always needs to be put into a rigorous instrumentation and mathematical context. Admittedly, the membership was not necessarily 100% optimistic, but we are all striving to continue to improve our own work by incorporating the insights and successes of our IABR colleagues. The personal contacts and interactive discussions at IABR provide unique value that can only be derived from physically attending a conference. With respect to conference itself, one of the challenges we are now facing is an outcome of our own success. We had about twice the expected attendance this year and it was tough to accommodate everyone who wanted to present his or her work. We had to run multiple sessions of short talks lasting well into the evening. It was hard work for the attendees who would perhaps have rather been sightseeing in Italy, but the interest in the work kept the conference rooms packed. So, what's next? We're all now gearing up for the 2012 conference in Oxford, UK. We expect a continuing growth in interest in all aspects of breath analysis and so need to do some serious planning based on lessons learned. Maybe it's time to add a day, shorten invited talks, add more parallel sessions, or some other approach. We're sure that the organizers of the next meeting will welcome any suggestions, so let them know. This report has been subjected to (EPA) Agency review and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

Breath analysis science at PittCon 2012, Orlando, Florida

The 2011 International Association of Breath Research (IABR) meeting in Parma, Italy: a collection of comments from attendees

High-Pressure Photon Ionization Source for TOFMS and Its Application for Online Breath Analysis.

Continuous Real Time Breath Gas Monitoring in the Clinical Environment by Proton-Transfer-Reaction-Time-of-Flight-Mass Spectrometry

Submarines, spacecraft and exhaled breath

Exhaled breath analysis: the new frontier in medical testing

Real-time breath analysis towards a healthy human breath profile

Emissions and uptake of volatiles by sampling components in breath analysis

Targeted breath analysis: exogenous volatile organic compounds (EVOC) as metabolic pathway-specific probes

Physiological modeling of isoprene dynamics in exhaled breath

Breath analysis-performance and potential of ion mobility spectrometry

Exhaled Breath Analysis: from Laboratory Test to Wearable Sensing

Integration of electronic nose technology with spirometry: validation of a new approach for exhaled breath analysis

Real-Time Non-Invasive Monitoring of Short-Chain Fatty Acids in Exhaled Breath

Late Breaking Abstract - Assessing Inflammatory Response to Air Pollution via VOCs in Exhaled Breath

New perspectives on 'Breathomics': metabolomic profiling of non-volatile organic compounds in exhaled breath using DI-FT-ICR-MS

Current breathomics--a review on data pre-processing techniques and machine learning in metabolomics breath analysis

Online mass spectrometry of exhaled breath with a modified ambient ion source

Volatile compounds in blood headspace and nasal breath

Role of exhaled breath biomarkers in environmental health science

150 Keynote: A New Aerosol Mass-Spectrometer for Simultaneous Detection of Health-Relevant Polycyclic Aromatic Hydrocarbons, Soot and Inorganic Components from Individual Airborne Particles